Suppr超能文献

相似文献

1
Multiparametric immune profiling in HPV- oral squamous cell cancer.
JCI Insight. 2017 Jul 20;2(14). doi: 10.1172/jci.insight.93652.
2
Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.
Cancers (Basel). 2021 Feb 4;13(4):620. doi: 10.3390/cancers13040620.
5
Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15.
6
Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer.
Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.
8
Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma.
Oncotarget. 2017 Aug 3;8(39):66178-66194. doi: 10.18632/oncotarget.19842. eCollection 2017 Sep 12.
10
Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining.
J Oral Pathol Med. 2008 Sep;37(8):485-9. doi: 10.1111/j.1600-0714.2008.00641.x. Epub 2008 Mar 18.

引用本文的文献

1
GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors.
Cancer Immunol Immunother. 2025 Sep 13;74(10):308. doi: 10.1007/s00262-025-04157-2.
2
The regulatory role and mechanism of energy metabolism and immune response in head and neck cancer.
Genes Dis. 2025 Mar 19;12(6):101607. doi: 10.1016/j.gendis.2025.101607. eCollection 2025 Nov.
4
The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patterns.
NPJ Precis Oncol. 2025 Jul 1;9(1):217. doi: 10.1038/s41698-025-00983-w.
6
HIV status alters immune cell infiltration and activation profile in women with breast cancer.
Nat Commun. 2025 May 20;16(1):4699. doi: 10.1038/s41467-025-59408-8.
7
Assessment of immune infiltrate in oral cancer: An immunohistochemical study.
J Oral Maxillofac Pathol. 2025 Jan-Mar;29(1):66-75. doi: 10.4103/jomfp.jomfp_184_24. Epub 2025 Mar 28.
10

本文引用的文献

1
Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges.
Curr Opin Immunol. 2017 Apr;45:60-72. doi: 10.1016/j.coi.2017.01.005. Epub 2017 Feb 20.
4
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Nature. 2016 Jun 16;534(7607):402-6. doi: 10.1038/nature18294. Epub 2016 May 23.
5
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Blood. 2016 Jun 16;127(24):3026-34. doi: 10.1182/blood-2015-12-686550. Epub 2016 Mar 30.
7
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
Clin Cancer Res. 2016 Jul 15;22(14):3571-81. doi: 10.1158/1078-0432.CCR-15-2665. Epub 2016 Feb 10.
8
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016.
9
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
PLoS One. 2015 Nov 12;10(11):e0142656. doi: 10.1371/journal.pone.0142656. eCollection 2015.
10
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.
J Immunother Cancer. 2015 Oct 20;3:47. doi: 10.1186/s40425-015-0091-z. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验